<SEC-DOCUMENT>0001062993-26-000102.txt : 20260107
<SEC-HEADER>0001062993-26-000102.hdr.sgml : 20260107
<ACCEPTANCE-DATETIME>20260107172757
ACCESSION NUMBER:		0001062993-26-000102
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260107
FILED AS OF DATE:		20260107
DATE AS OF CHANGE:		20260107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRIGHT MINDS BIOSCIENCES INC.
		CENTRAL INDEX KEY:			0001827401
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40997
		FILM NUMBER:		26516664

	BUSINESS ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		6474072515

	MAIL ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>

<head>
    <title>Bright Minds Biosciences Inc.: Form 6-K - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><font style="font-size: 18pt;"><b>UNITED STATES</b></font><br><font style="font-size: 18pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></font><br><b>Washington, D.C.&#160; 20549</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><font style="font-size: 18pt;"><b>FORM 6-K</b></font></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;">For the month of <u><b>January 2026</b></u></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;">Commission File No.<u> <b>001-40997</b></u></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><font style="font-size: 18pt;"><u><b>BRIGHT MINDS BIOSCIENCES INC.</b></u></font><br><font style="font-size: 10pt;">(Translation of registrant's name into English)</font></p>
    <table style="border-collapse: collapse; font-size: 10pt; width: 100%;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><b>400 N Aberdeen St Suite 900</b><br><u><b>Chicago, IL 60642</b></u><br>(U.S. Corporate headquarters)</td>
            <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle; text-align: center;"><b>1122 Mainland St #228</b><br><u><b>Vancouver, BC V6B 5L1</b></u><br>(Canadian Corporate headquarters)</td>
        </tr>
    </table>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F</p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;">Form 20-F&#160; [ ]&#160; <b>Form 40-F [ X ]</b></p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_2"></a>
    <p style="text-align: justify; background-color: #ffffff; margin-top: 10pt; margin-bottom: 10pt;">On January 7, 2026, Bright Minds Biosciences Inc. (the "Company"), Piper Sandler &amp; Co. ("Piper Sandler") and Cantor Fitzgerald &amp; Co. ("Cantor") mutually agreed to terminate the Equity Distribution Agreement, dated August 25, 2025, between the Company, Piper Sandler and Cantor, effective January 7, 2026.</p>
    <p style="text-align: center; background-color: #ffffff; margin-top: 10pt; margin-bottom: 10pt;"><b>INCORPORATION BY REFERENCE</b></p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">The disclosure in this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No. 333-284694) filed on February 5, 2025, and (b) registration statement on Form F-3 (File No. 333-289851) filed on August 26, 2025.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_3"></a>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>SIGNATURE</b></p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 50%;">&#160;</td>
            <td style="width: 50%;"><b>BRIGHT MINDS BIOSCIENCES INC.</b></td>
        </tr>
        <tr>
            <td style="width: 50%;">&#160;</td>
            <td style="width: 50%;">&#160;</td>
        </tr>
        <tr>
            <td style="width: 50%;">&#160;</td>
            <td style="width: 50%; border-bottom: 0.75pt solid #000000;"><i>/s/ Ryan Cheung</i></td>
        </tr>
        <tr>
            <td style="width: 50%;">&#160;</td>
            <td style="width: 50%;">Ryan Cheung</td>
        </tr>
        <tr>
            <td style="width: 50%;">&#160;</td>
            <td style="width: 50%;">Chief Financial Officer</td>
        </tr>
    </table>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Date:&#160; January 7, 2026</p>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
